Next Article in Journal
Analysis of the Hypoxic Response in a Mouse Cortical Collecting Duct-Derived Cell Line Suggests That Esrra Is Partially Involved in Hif1α-Mediated Hypoxia-Inducible Gene Expression in mCCDcl1 Cells
Previous Article in Journal
Anxiety-like Behavior and GABAAR/BDZ Binding Site Response to Progesterone Withdrawal in a Stress-Vulnerable Strain, the Wistar Kyoto Rats
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 13
10.3390/ijms23137261
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data

by
Annunziata Nusca
1,*,
Francesco Piccirillo
1,
Federico Bernardini
1,
Aurelio De Filippis
1,
Federica Coletti
1,
Fabio Mangiacapra
1,
Elisabetta Ricottini
1,
Rosetta Melfi
1,
Paolo Gallo
1,
Valeria Cammalleri
1,
Nicola Napoli
2,
Gian Paolo Ussia
1 and
Francesco Grigioni
1
1
Unit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, 00128 Rome, Italy
2
Unit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University of Rome, 00128 Rome, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(13), 7261; https://doi.org/10.3390/ijms23137261
Submission received: 31 May 2022 / Revised: 24 June 2022 / Accepted: 27 June 2022 / Published: 30 June 2022
(This article belongs to the Special Issue Frontiers in Cardiometabolic Diseases)
Browse Figures
Review Reports Versions Notes

Abstract

Coronary artery disease (CAD) remains one of the most important causes of morbidity and mortality worldwide, and revascularization through percutaneous coronary interventions (PCI) significantly improves survival. In this setting, poor glycaemic control, regardless of diabetes, has been associated with increased incidence of peri-procedural and long-term complications and worse prognosis. Novel antidiabetic agents have represented a paradigm shift in managing patients with diabetes and cardiovascular diseases. However, limited data are reported so far in patients undergoing coronary stenting. This review intends to provide an overview of the biological mechanisms underlying hyperglycaemia-induced vascular damage and the contrasting actions of new antidiabetic drugs. We summarize existing evidence on the effects of these drugs in the setting of PCI, addressing pre-clinical and clinical studies and drug-drug interactions with antiplatelet agents, thus highlighting new opportunities for optimal long-term management of these patients.
Keywords: glycaemic control; hyperglycaemia; glycaemic variability; diabetes mellitus; coronary artery disease; percutaneous coronary intervention; coronary stenting; anti-diabetic agents glycaemic control; hyperglycaemia; glycaemic variability; diabetes mellitus; coronary artery disease; percutaneous coronary intervention; coronary stenting; anti-diabetic agents

Share and Cite

MDPI and ACS Style

Nusca, A.; Piccirillo, F.; Bernardini, F.; De Filippis, A.; Coletti, F.; Mangiacapra, F.; Ricottini, E.; Melfi, R.; Gallo, P.; Cammalleri, V.; et al. Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. Int. J. Mol. Sci. 2022, 23, 7261. https://doi.org/10.3390/ijms23137261

AMA Style

Nusca A, Piccirillo F, Bernardini F, De Filippis A, Coletti F, Mangiacapra F, Ricottini E, Melfi R, Gallo P, Cammalleri V, et al. Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. International Journal of Molecular Sciences. 2022; 23(13):7261. https://doi.org/10.3390/ijms23137261

Chicago/Turabian Style

Nusca, Annunziata, Francesco Piccirillo, Federico Bernardini, Aurelio De Filippis, Federica Coletti, Fabio Mangiacapra, Elisabetta Ricottini, Rosetta Melfi, Paolo Gallo, Valeria Cammalleri, and et al. 2022. "Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data" International Journal of Molecular Sciences 23, no. 13: 7261. https://doi.org/10.3390/ijms23137261

APA Style

Nusca, A., Piccirillo, F., Bernardini, F., De Filippis, A., Coletti, F., Mangiacapra, F., Ricottini, E., Melfi, R., Gallo, P., Cammalleri, V., Napoli, N., Ussia, G. P., & Grigioni, F. (2022). Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. International Journal of Molecular Sciences, 23(13), 7261. https://doi.org/10.3390/ijms23137261

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop